| Program | Target/MOA | Indication | Research | Preclinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|---|---|
| tRNA synthetase programs | |||||||
| Efzofitimod | NRP2 modulator | Pulmonary Sarcoidosis1 |
|
||||
| SSc-ILD |
|
||||||
| Other ILD (CTD-ILD; CHP) |
|
||||||
| ATYR0101 | LTBP1 modulator | Fibrosis |
|
||||
| ATYR0750 | FGFR4 modulator | Liver Disorders |
|
||||
| Monoclonal antibody programs | |||||||
| ATYR2810 | NRP2/VEGF antagonist | Solid Tumors |
|
||||
| ATYR4010 | NRP2/CCR7 antagonist | Autoimmune Disease |
|
||||
| Program/ Target |
Indication | Phase | |||||
|---|---|---|---|---|---|---|---|
| tRNA synthetase programs | |||||||
| Efzofitimod (ATYR1923) NRP2 modulator |
Pulmonary Sarcoidosis1 | Phase 3 | |||||
| SSc-ILD | Phase 2 | ||||||
| Other ILD (CTD-ILD; CHP) | Phase 1 | ||||||
| ATYR0101 LTBP1 modulator |
Fibrosis | Research | |||||
| ATYR0750 FGFR4 modulator |
Liver Disorders | Research | |||||
| Monoclonal antibody programs | |||||||
| ATYR2810 NRP2/VEGF antagonist |
Fibrosis | Research | |||||
| ATYR4010 NRP2/CCR7 antagonist |
Autoimmune Disease | Preclinical | |||||
(1) In partnership with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILD in Japan
SSc-ILD = Scleroderma-related ILD; CTD-ILD = Connective Tissue Disease-ILD; CHP = Chronic Hypersensitivity Pneumonitis